{"id":851991,"date":"2025-05-16T16:03:10","date_gmt":"2025-05-16T20:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/"},"modified":"2025-05-16T16:03:10","modified_gmt":"2025-05-16T20:03:10","slug":"cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/","title":{"rendered":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., May  16, 2025  (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting\u00a0to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their employment.<\/p>\n<p align=\"justify\">The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee\u2019s continued service with the Company. The stock options that were granted are subject to an exercise price of $29.84 per share, which is equal to the closing price of the Company\u2019s common stock on May 15, 2025, and will vest over 4 years, with 1\/4<sup>th<\/sup> of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1\/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee\u2019s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company&#8217;s Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.<\/p>\n<p align=\"justify\">The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of <em>aficamten, <\/em>a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). <em>Aficamten<\/em> is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing <em>omecamtiv mecarbil<\/em>, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from <em>aficamten, <\/em>for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.<\/p>\n<p align=\"justify\">For additional information about Cytokinetics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TZZ8C1AJDYvrXeblgu8WnLASt_mfz12z2B7sNwhBHwRC_QD8LLidKpUngCso9Q-oDwzlSIhNwBo2qOK1MYqFxQvPEAbutfhedisL_i20zcU=\" rel=\"nofollow\" target=\"_blank\">www.cytokinetics.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9aPOdePTDkf2qHFoI51B8-5C3qPIDYq-mC2lfvc5JrqTO6hIsOEpbGWawpmaaK3uik8y_4LuJ0LkpxneS87ldw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fd61Nj44t3f2Ho3ZZHMRGbdxS-k0GeVPmQEPXmnvbhlN7a0dqBJ0lQfyxQ2yVjj46YMiIAXZpV5OXN9t7_0IE71nTVI1CqXiXRyDA2B2EibZLy1LaRPkFYvFy7p8OAAI\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tEE9jGUF6moRvWA4DOMrF5Y34BogaeEy6wn1CIc2bjmZFPtUCmdH3b6geKhTOZzuo7mMX0ZnJ6-0eV3IU0QL418xPnzGA6Ad1YhxPLfx3G8=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xhsYqmQSt3EPuL5cqI5PuJnRC-i1pMdpkXZaWU5c9f4pM7vs7JWJ4cKCEr7rYwKegojRzAbMxox3fNt0xyevtQyIw0PnnmXEpX_HI2QLXcZ7WxwnAInKE5z2tM05D-8w\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the &#8220;Act&#8221;).\u00a0Cytokinetics\u00a0disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act&#8217;s\u00a0Safe Harbor\u00a0for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to\u00a0Cytokinetics&#8217;\u00a0and its partners&#8217; research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management&#8217;s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to\u00a0Cytokinetics&#8217;\u00a0business outlined in\u00a0Cytokinetics&#8217;\u00a0filings with the\u00a0Securities and Exchange Commission particularly under the caption \u201cRisk Factors\u201d in Cytokinetics\u2019 latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and\u00a0Cytokinetics&#8217;\u00a0actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that\u00a0Cytokinetics\u00a0makes in this press release speak only as of the date of this press release.\u00a0Cytokinetics\u00a0assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"justify\">CYTOKINETICS\u00ae and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.<\/p>\n<p>Contact:<br \/>Cytokinetics<br \/>Diane Weiser<br \/>Senior Vice President, Corporate Affairs<br \/>(415) 290-7757<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDVmMmYzMzItMjc4MS00NTMxLTg2NDctNDE2NmZlOGY5ZDE5LTEwMTY2NzYtMjAyNS0wNS0xNi1lbg==\/tiny\/Cytokinetics-Incorporated.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting\u00a0to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-851991","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting\u00a0to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in &hellip; Continue reading &quot;Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-16T20:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2025-05-16T20:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/\"},\"wordCount\":690,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/\",\"name\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=\",\"datePublished\":\"2025-05-16T20:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting\u00a0to 5 employees, whose employment commenced in April and May, 2025, as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in &hellip; Continue reading \"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-16T20:03:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2025-05-16T20:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/"},"wordCount":690,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/","name":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=","datePublished":"2025-05-16T20:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MzQyNCM2OTQ2OTE2IzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-35\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=851991"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851991\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=851991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=851991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=851991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}